NCT00668304View on ClinicalTrials.gov

Trial to Evaluate Time to Symptom Relief and Elimination of Infecting Bacteria in Treating Sinusitis With Avelox

PHASE4CompletedINTERVENTIONAL
Enrollment

192

Participants

Timeline

Start Date

June 30, 2004

Study Completion Date

January 31, 2005

Conditions
Maxillary Sinusitis
Interventions
DRUG

Avelox (Moxifloxacin, BAY12-8039)

Moxifloxacin 400 mg once orally daily

Trial Locations (35)

1416

Buenos Aires

1888

San Juan Bautista

2000

Rosario

4000

San Miguel de Tucumán

5000

Córdoba

11758

North Massapequa

14618

Rochester

17110

Harrisburg

22601

Winchester

22902

Charlottesville

23229

Richmond

29118

Orangeburg

29607

Greenville

35206

Birmingham

38301

Jackson

43235

Columbus

48202

Detroit

71105

Shreveport

72143

Searcy

72401

Jonesboro

73099

Yukon

73120

Oklahoma City

75010

Carrollton

80501

Longmont

80909

Colorado Springs

84102

Salt Lake City

92506

Riverside

93720

Fresno

94102

San Francisco

97035

Lake Oswego

35216-5453

Hoover

06606

Bridgeport

32720-2560

DeLand

99202-1334

Spokane

C1280AEB

Buenos Aires

Sponsors

Lead Sponsor

Bayer
All Listed Sponsors
lead

Bayer

INDUSTRY

NCT00668304 - Trial to Evaluate Time to Symptom Relief and Elimination of Infecting Bacteria in Treating Sinusitis With Avelox | Biotech Hunter | Biotech Hunter